



IDF 2025
BANGKOK
7-10 APRIL

**INDUSTRY
AND SATELLITE
SYMPOSIA GUIDE**



idf2025.org





TABLE OF CONTENTS

Congress-at-a-glance	3
Satellite symposia overview	4
Venue location map	9
Venue floor plan	10
Exhibition floor plan	14
Global village	16
Company and organisation profiles	18
Satellite symposia programme by day	24

The content of this publication reflects the situation at the time of print and may be subject to change. The organiser cannot be held liable for any inconvenience resulting from these changes.

CONGRESS-AT-A-GLANCE

The time zone for the IDF World Diabetes Congress 2025 is ICT (UTC +7)

	Monday 7 Apr	Tuesday 8 Apr	Wednesday 9 Apr	Thursday 10 Apr	
08.30		Scientific Sessions	Scientific Sessions	Scientific Sessions	
10.00	Satellite Symposia & Pre Congress sessions	Coffee break	Coffee break	Coffee break	
10.30		Scientific Sessions	Scientific Sessions	Scientific Sessions	
12.00					
12.30		E-Posters	E-Posters	E-Posters	
		Satellite Symposia	Satellite Symposia	Satellite Symposia	
13.30					
13.45		Scientific Sessions	Exhibition	Scientific Sessions	Exhibition
14.45					
15.00		Scientific Sessions	Scientific Sessions	Scientific Sessions	Scientific Sessions
15.45					
16.00		Scientific Sessions	Scientific Sessions		
16.30					
17.00	Opening				
17.30		Satellite Symposia	Satellite Symposia		
18.00	Welcome Reception				
19.30			Get-Together Evening		
20.00					
22.00					

SATELLITE SYMPOSIA OVERVIEW

MONDAY

MONDAY 7 APRIL 2025

10:00 - 11:45	Silk 1	Diabetes India
Diabetes India		
12:15 - 14:00	Silk 1	Diabetes Asia Study Group (DASG)
Diabetes Asia Study Group (DASG)		
14:30 - 16:30	Silk 1	Xi'an Jiaotong University Health Science Center
Diabetes in Asia: Understanding risk, environment, and innovative management strategies in China and beyond		
12:00 - 14:00	Nile 1	Abbott Libre Academy
Revolutionizing Diabetes Care CGM essentials to unlocking progress		

TUESDAY

TUESDAY 8 APRIL 2025

12:30 - 13:30	Amber	P&G Health
Shape the future of nerve health - Empower the patient		
12:30 - 13:30	Grand Hall 201	Abbott Nutrition
Implementing MNT in diabetes management: Time to move the needle		
17:30 - 19:30	Grand Hall 201	#dedoc
What we wish you knew - and why		
12:30 - 13:30	Grand Hall 202	Sciarc
Optimizing care in heart failure, Chronic kidney disease and diabetes with non-steroidal MRAs		
12:30 - 13:30	Nile 1	Lilly
New insights into treatment of type 2 diabetes		
17:30 - 19:30	Nile 1	World Diabetes Foundation (WDF) - IDF
The time is now: Improving access to diabetes care in a strengthened global policy framework		
12:30 - 13:30	Nile 2	AusMedGlobal
The Beauty and opportunity of breath ketone to transform diabetes care		
17:30 - 19:30	Nile 2	Lilly
Global health session "How the private sector can help improve access to health care: A case of Lilly"		
12:30 - 13:30	Silk 1	Servier
Assessing and addressing needs in T2D for glycaemic control, cardiorenal protection and adherence: What are our options?		

TUESDAY 8 APRIL 2025 (CONTINUED)17:30 - 19:30 Silk 2 **Abbott****From Namaste to Sawasdee: A night of continuous connection**12:30 - 13:30 Meeting room 216 **World Health Organisation (WHO)****Bridging gaps: Integrated strategies to address TB and diabetes****NOTES**

WEDNESDAY 9 APRIL 202512:30 - 13:30 Amber **Roche Diabetes Care****Holistic and connected diabetes management:
Insights from the patient's perspective**12:30 - 13:30 Diabetes Spotlight **P&G Health****Breaking barriers in peripheral neuropathy management-
From silent suffering to superior treatment**17:30 - 18:30 Grand Hall 201 **World Health Organisation (WHO) - IDF****4th Global Diabetes Compact Anniversary**12:30 - 13:30 Grand Hall 202 **Abbott****Revolutionizing diabetes care with CGM:
Innovation for accessibility and ease**12:30 - 13:30 Nile 1 **Lilly****Seeing beyond the numbers in type 2 diabetes:
Empowering patients for optimal weight and glycaemic management**17:30 - 19:00 Nile 2 **Japi****Advance in diabetes management and metabolic health:
Perspectives from India and SEA**12:30 - 13:30 Silk 1 **Merck****Metformin and insulin resistance: Bridging science and clinical practice**12:30 - 13:30 Silk 2 **Hetero****Early combinational therapy of DPP-4i Plus SGLT2i:
Patient profile, approaches, strategies, guidelines, and pitfalls**


VENUE FLOOR PLAN



Legend Ground floor	
1	Registration
2	Exhibition Hall 98
	Exhibition booths
	Global Village & IDF Stand
	E-Poster terminals
	CME certificates
	IDF Lounge
	Diabetes spotlight
	Catering
Congress bag	

3	First aid
4	Welcome Foyer West - Meet & greet
5	Media center
6	Get Together event - Sama Garden

VENUE FLOOR PLAN



Legend Convention Floor	
1	Session halls
	Grand Hall 201
	Grand Hall 202
	Silk 1
	Silk 2
	Nile 1
	Nile 2
Amber	

2	Speaker preview room
3	IDF Meeting room 216
4	IDF Meeting room 217
5	Young Leaders in Diabetes
6	MedComax interview hub
7	Opening ceremony

Booth	Region	Country	Member
AA01	SACA	Venezuela	Federación Nacional de Asociaciones y Unidades de Diabetes
AA02	SACA	Peru	Asociación de Diabéticos Juveniles del Péru
AA03	SACA	El Salvador	Asociación Salvadoreña de Diabetes
AA04	SACA	Brazil	Associação de Diabetes Juvenil
AA05	SACA	Argentina	Sociedad Argentina de Diabetes
AA06	SACA	Argentina	Federación Argentina de Diabetes
AA07	AFR	Ghana	National Diabetes Association
AA08	AFR	Gambia	Gambian Diabetes Association
AA09	AFR	Ethiopia	Ethiopian Diabetes Association
AA10	AFR	Eswatini	Diabetes Eswatini
AA11	AFR	Eritrea	Eritrean National Diabetic Association
AA12	AFR	Dem. Rep. of Congo	Association Vaincre le Diabète au Congo
AA13	AFR	Côte d'Ivoire	Association Obésité et Diabète de Côte d'Ivoire
AA14	AFR	Côte d'Ivoire	Association des Diabétiques de Côte d'Ivoire
AA15	AFR	Cameroon	Cameroon Diabetes Association
AA16	AFR	Burkina Faso	Association Burkinabe d'Aide aux Diabétiques
AA17	SACA	Venezuela	Sociedad Venezolana de Endocrinología y Metabolismo
AA18	SEA	Bangladesh	Bangladesh Endocrine Society
AA19	SEA	Bangladesh	Diabetic Association of Bangladesh
AA20	SEA	India	Research Society for the Study of Diabetes in India
AA21	SEA	India	The Research Trust of DiabetesIndia
AA22	AFR	Madagascar	Association Malgache contre le Diabète
AA23	AFR	Mauritania	Association Mauritanienne de Lutte contre le Diabète
AA24	AFR	Nigeria	Diabetes Association of Nigeria
AA25	AFR	Rep of Congo	Diabaction-Congo

Booth	Region	Country	Member
AA26	AFR	Rwanda	Association Rwandaise des Diabétiques
AA27	AFR	Senegal	Association Sénégalaise de Soutien aux Diabétiques
AA28	AFR	Seychelles	Diabetic Society of Seychelles
AA29	AFR	Tanzania	Tanzania Diabetes Association
AA30	AFR	Togo	Association Togolaise du Diabete
AA31	AFR	Uganda	Uganda Diabetes Association
AA32	AFR	Zimbabwe	Zimbabwe Diabetic Association
BB01	MENA	Iran	Gabric
BB02	MENA	Egypt	Arabic Association for the Study of Diabetes & Metabolism
BB03	MENA	Bahrain	Bahrain Diabetes Society
BB04	SEA	Maldives	Diabetes Society of Maldives
BB05	SEA	Sri Lanka	Diabetes Association of Sri Lanka
BB10	MENA	Iran	Iranian Diabetes Society
BB11	MENA	Jordan	Jordanian Society for the Care of Diabetes
BB12	MENA	Kuwait	Kuwait Diabetes Society
BB13	MENA	Lebanon	Chronic Care Center
BB14	MENA	Lebanon	DiaLeb
BB33	EUR	Germany	EASD
BB35	EUR	Georgia	Georgian Union of Diabetes and Endocrine Associations
BB37	EUR	Azerbaijan	Azerbaijan Diabetes League
BB39	EUR	Albania	Albanian Diabetes Association
BB32	EUR	Italy	Associazione Italiana per la Difesa degli Interessi dei Diabetici
BB34	EUR	Italy	Associazione Medici Diabetologi
BB36	EUR	Kazakhstan	Diabetes Association of the Republic of Kazakhstan
BB38	EUR	Latvia	Latvian Diabetes Association
CC01	MENA	Pakistan	National Association of Diabetes Educators of Pakistan
CC02	MENA	Pakistan	Diabetic Association of Pakistan

Booth	Region	Country	Member
CC03	MENA	Morocco	Ligue Marocaine de Lutte contre le Diabète
CC04	MENA	Libya	Libyan Diabetic Association
CC05	MENA	Lebanon	Lebanese Diabetes Association
CC40	EUR	Slovakia	ZVAZ Diabetikov Slovenska
CC41	EUR	Serbia	Diabetes Association of Serbia
CC42	EUR	Poland	Polskie Stowarzyszenie Diabetyków / Polskie Towarzystwo Diabetologiczne
CC43	EUR	North Macedonia	Union of Associations of Persons with Diabetes of Macedonia
DD01	MENA	Pakistan	Primary Care Diabetes Association
DD02	MENA	Pakistan	Pakistan Diabetes Society
DD03	MENA	Pakistan	Pakistan Endocrine Society
DD04	MENA	Palestine	Diabetes Palestine
DD05	MENA	Saudi Arabia	Saudi Charitable Association of Diabetes
DD10	MENA	UAE	Emirates Diabetes Society
DD11	MENA	Tunisia	Association of Endocrinologists-Diabetologists of Sfax
DD12	MENA	Diabetes in Asia Study Group	
DD13	MENA	Qatar	Qatar Diabetes Association
DD14	MENA	Saudi Arabia	Sheffaa
DD27	EUR	Slovenia	Zveza Drustev Diabetikov Slovenije
DD28	EUR	Uzbekistan	Endocrinological and Diabetes Association of Uzbekistan
DD29	EUR	Spain	Sociedad Española de Diabetes
DD30	EUR	Uzbekistan	Charity Association of Persons with Disabilities and People with Diabetes Mellitus
DD31	EUR	Turkey	Turkish Diabetes Association
DD32	EUR	Ukraine	Ukrainian Diabetic Federation
DD33	EUR	Turkey	Turkish Diabetes Foundation
DD34	EUR	Ukraine	International Diabetes Association of Ukraine

Booth	Region	Country	Member
EE07	NAC	Bermuda	Bermuda Diabetes Association
EE08	WP	Philippines	Diabetes Philippines
EE09	WP	Korea	Korean Diabetes Society
EE10	WP	Korea	Korean Diabetes Association
EE11	WP	Japan	Japan Diabetes Society
EE12	WP	Indonesia	Persatuan Diabetes Indonesia
EE13	WP	Fiji	Diabetes Fiji
EE14	WP	Cambodia	Cambodian Diabetes Association
EE15	WP	Australia	Diabetes Australia
EE22	NAC	USA	Direct Relief
EE23	WP	Philippines	The Philippine College of Endocrinology, Diabetes and Metabolism
EE24	WP	Singapore	Diabetes Singapore
EE26	WP	Taiwan, China	Chinese Taipei Diabetes Association
EE27	WP	Taiwan, China	Taiwanese Association of Diabetes Educators
EE28	WP	Thailand	Diabetes Association of Thailand
EE29	WP	Thailand	Thai Association of Diabetes Educators
EE30	WP	Transnational	Action4Diabetes

COMPANY AND ORGANISATION PROFILES

Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

Actxa

Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.

Almond Board of Australia

The Almond Board of Australia is the peak body representing Australia's almond growers, processors, and marketers. We promote the major Australian almond exporters and communicate the key attributes of Australian almonds, which are rich in protein, fibre, healthy fats, Vitamin E, and Magnesium.

Ascensia Diabetes Care

Ascensia Diabetes Care is a global company dedicated to improving the health and lives of people with diabetes. We created the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and are the exclusive global distribution partner for the Eversense® CGM Systems. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives.

AstraZeneca

AstraZeneca, a leading science-led biopharmaceutical company with over 40 years history in Thailand. The company is committed to creating life-changing innovative medicines and improving access to the Thai community. We are dedicated to improving patient outcomes and transforming the future of healthcare by harnessing the power of science to build a healthy future for Thai people, society and the planet. AstraZeneca Thailand's therapy area covers Cardiovascular, Renal and metabolism (CVRM), Respiratory, Immunology, Vaccines, and Immune Therapies (RIVIT), Oncology, and Rare Disease. With more than 350 highly qualified employees and over 20 medicines in the company portfolio. AstraZeneca focuses on delivering the greatest benefits to patients, healthcare systems, and societies.

AusMedGlobal

AusMed Global is a global leader in non-invasive ketone technologies to combat diabetes, obesity, and beyond. With integrated hardware, software, and API connectivity options, our technologies provide critical, easy-to-use, personalised ketone analysis for point-of-care and home use, with great potentials for seamless integration into healthcare and insurance systems. Our *KetoMetrics* ketone technologies support evidence-based ketone therapies for a variety of conditions, including cardiovascular diseases, certain types of cancer, Alzheimer's disease, bipolar disorder, concussion, non-alcoholic fatty liver disease (NAFLD), in-vitro fertilization (IVF), ketone supplementation, sports science, and PET imaging. We are actively expanding our collaboration with strategic global partners to transform diabetes care, promote holistic health, and support healthy longevity for individuals around the world.

#dedoc

#dedoc° runs the world's largest scholarship programme for diabetes advocates. Every year, we empower hundreds of #dedoc° voices to attend ATTD, EASD and ISPAD as well as other national and regional congresses around the world – including the IDF World Diabetes Congress. They speak at scientific sessions and symposia, engage with HCPs, researchers, policy makers and key stakeholders and report back to their communities.

Dr Reddy's Laboratories

Dr. Reddy's Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future.

Encore

Encore Medical Education is pleased to be a partner of IDF and responsible for organising Best of IDF programmes for clinicians around the world. The mission of Encore Medical Education is to provide gold standard, postgraduate, independent medical education to physicians to improve patient care outcomes across the globe.

Hetero

Hetero is a globally renowned, vertically integrated pharmaceutical company engaged in R&D, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Established in 1993 in Hyderabad, India, its key business areas include APIs, Global Generics, Biosimilars, and CDMO. Among the world's largest API producers, Hetero's 29,000+ workforce spans six continents, operating 38 state-of-the-art manufacturing facilities and 60 global locations, supplying medicines to 145+ countries.

Japi

The Journal of the Association of Physicians of India (JAPI), established in 1952, is the leading scientific journal in India, reaching over 22,000 active members of the Association of Physicians of India

every month. For over six decades, JAPI has served as a trusted platform for disseminating practice guidelines, original research, and literature tailored to the Indian healthcare ecosystem. Our extensive publications on diabetes and its comorbidities have been instrumental in addressing the growing epidemic and providing evidence-based approaches for healthcare professionals.

LG CHEM

Since its establishment in 1947, LG Chem has continuously achieved growth through endless challenges and innovations as Korea's leading chemical company. LG Chem will endeavor to become a 'Global Top 5 Chemical Company' with a balanced business portfolio that has a competitive advantage across the globe, including business divisions in petrochemicals, advanced materials, life sciences, and batteries.

Life for a Child

Life for a Child is a programme of Diabetes Australia. IDF is a partner in the work. Life for a Child supports diabetes centres caring for children and youth with diabetes in less-resourced countries. Currently over 60,000 young people are being helped in 53 countries, and we are open to potentially supporting other countries. The programme's vision is that 'No child should die of diabetes'.

Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.

MDE Technologies

MDE Technologies manufactures the all-new Neurometer peripheral neuropathy tester and Cardiologic autonomic neuropathy tester. We provide user-friendly, automated, portable medical devices that deliver quantifiable diagnostic data for monitoring diabetes complications. We believe that quantifiable data is one of the most useful tools available to today's healthcare profession. We believe that user-friendly, automated, portable medical devices are the key to providing easier access to improved screening and monitoring of diabetes complications. We believe that easier access to improved screening and monitoring is the best way to help healthcare professionals provide the recommended care for their patients with diabetes.

Merck

Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices, the company is everywhere. In 2020 Merck generated sales of € 17.5 billion in 66 countries. Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics in electronics.

MicroMedTech

Since 2011, MicroTech Medical has focused on better diabetes care, with an eye on innovation, sustainability, and affordability. Its solutions include insulin pumps, glucose monitoring systems, and POCT products, available globally. Dedicated to helping people with diabetes, MicroTech Medical offers personalised services and aids healthcare decisions for a more normal life.

Mitsubishi Tanabe Pharma

Founded in 1678 and based in Osaka, Japan, Mitsubishi Tanabe Pharma Corporation (MTPC) is one of the world's oldest pharmaceutical companies. MTPC's mission is "Creating hope for all facing illness," which they pursue through ethical pharmaceuticals targeting key disease areas: diabetes and kidney diseases, central nervous system disorders, immuno-inflammatory diseases, and cancer. MTPC is committed to "precision medicine," focusing on identifying patient populations who will benefit most from their therapies in terms of efficacy and safety.

Optomed

Optomed is a Finnish medical technology company and a leading provider of handheld fundus cameras. Our AI-powered screening solutions aim to transform diagnostic processes and empower early detection of various diseases, such as rapidly increasing diabetes-related retinopathy. Two decades of pioneering expertise, we design cutting-edge retinal imaging technology that is trusted by healthcare professionals worldwide. Our technology is extensively patented, clinically validated and has approvals in all key markets, including CE, FDA and CFDA. Optomed – Enabling Screening for All.

P&G Health

P&G Health, the health care division of P&G company, drives consumer-centric innovation to empower our consumers to live longer, healthier, and more vibrant lives. P&G Health has partnered with IDF on multiple occasions and is committed to raise disease awareness on Diabetic Peripheral Neuropathy (DPN) among people living with diabetes. This collaboration includes global initiatives such as stand-alone satellite symposia and research activities. By focusing on education about the symptoms and risks of DPN, P&G Health is devoted to improving the lives of people affected by diabetes and enhancing their understanding of nerve health.

Roche Diabetes Care

Our vision at Roche Diabetes Care is to help people with diabetes think less about their daily diabetes routines. Under the brands Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery and digital solutions, we unite with partners and thought leaders around the globe to facilitate integrated personalised diabetes management (iPDM) creating patient-centred value. By building and collaborating in an open ecosystem, connecting devices, and digital solutions as well as contextualising relevant data points, we drive deeper insights and innovation to enable a better understanding of the disease leading to personalised and effective therapy adjustments. For better outcomes and true relief.

Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi GHU

Sanofi Global Health Unit is a pioneering, not-for-profit social business model with a goal to improve the lives of underserved populations in 40 countries with the highest unmet medical needs through innovative inclusive healthcare models and partnerships, delivering a sustainable impact.

Sciarc GmbH

SCIARC is characterised by innovative solutions that are committed to the rapid changes in medicine at the beginning of the 21st century. The company stands for competent knowledge transfer in medicine, which is expressed in the areas of medical education - CME and webcasts - as well as medical writing and consulting. We also analyse complex research results with a view to clinical benefit and build the bridge to the correct implementation of scientific findings in clinics and medical practice.

Servier

Founded to serve health, Servier is a global group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,900 employees of the Group are committed to this shared vocation, a source of inspiration every day. Servier' growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neurosciences and immuno-inflammatory diseases.

Sinocare Medical

Sinocare is a high-tech company that employs biosensing technology to develop, produce, and sell various rapid diagnostic test products for chronic diseases, catering to both chronic disease patients and healthcare professionals. Alongside our product offerings, Sinocare also provides professional services and digital health management solutions specifically for diabetes.

SOT Medical Systems

SOT Medical Systems has been engaged in medical business for 30 years, within Austria and internationally. In 1991 the family business started operating in the fields of angiology, phlebology and cardiology. Since 1999, a system for the fast and reliable diagnosis of pAOD patients has been self-developed: the AngETM System. Due to its modularity, it constitutes the ideal solution for angiologists, phlebologists, vascular surgeons and for the diagnosis of people with diabetes. Made in Austria, our AngE products have been developed, produced and assembled at our headquarters in Carinthia since the beginning. While doing so, we pay close attention to observe the highest quality standards and invest steadily in the research and development of our leading vascular diagnostic systems.

YOURAH

YOURAH is IDF Europe's youth network, bringing together over 100 young diabetes advocates from across the European Region. Made up of alumni from the Youth Leadership Lab and Camp, YOURAH empowers young people living with diabetes to take an active role in advocacy, policymaking, and community building at local, national, and European levels. Young advocates collaborate with IDF Europe member associations, policymakers and NGOs, participate in EU-funded projects, and lead initiatives to keep diabetes high on the political agenda across Europe. Empowering youth with leadership skills, peer support, and cross-border cooperation, YOURAH ensures that young voices shape the present and the future of diabetes care and advocacy.

Yuwell Medical

Founded in 1998, Yuwell Medical is a leading Chinese medical device company, listed in 2008. With 12 R&D centers and 9 global production bases, it serves 300,000 medical institutions across 131 countries, benefiting 300 million households. Specializing in respiratory therapy, diabetes management and more, Yuwell leads in homecare and chronic disease management. Its 670,000 sq.m. manufacturing base, aligned with Industry 4.0, integrates intelligent production and digital services. Yuwell continues to innovate in medical health and life sciences.

PROGRAMME
MONDAY 7 APRIL

MONDAY 7 APRIL 2025

SATELLITE SYMPOSIUM

MONDAY

14:30 - 16:30

Silk 1

**Xi'an Jiaotong University Health Science Center:
Diabetes in Asia: Understanding risk, environment, and
innovative management strategies in China and beyond**

14:30

Welcome and Introduction

Chair: *Wang, Youfa (China)*

14:35

Disease burden of obesity and related chronic diseases in China and intervention efforts

Speaker: *Wang, Youfa (China)*

14:55

Trends in prevalence of diabetes, related management, and risk factors in China

Speaker: *Wang, Limin (China)*

15:15

Regional and ethnic disparities in obesity and related non- communicable diseases in China

Speaker: *Peng, Wen (China)*

15:35

**Diabetes Self-management in the digital age: Digital and intelligent diabetes shared-
care management Beijing model**

Speaker: *Zhang, Junqing (China)*

15:55

Practices of prevention and treatment of diabetes and its complications in China

Speaker: *Yang, Juhong (China)*

16:15

Diabetes prevention and treatment in East Asia - Emerging trends and future directions

Speaker: *Ma, Ronald (China)*

12:00 - 14:00 Nile 1

**Abbott Libre Academy: Revolutionizing diabetes care |
CGM essentials to unlocking progress**

12:00

Opening and Introduction*Chair: Deerochanawong, Chaicharn (Thailand)*

12:05

Beyond HbA1c: Enhancing diabetes care with CGM

12:15

Enhancing clinical outcomes with CGM: Evidence and insights

12:25

Overview of CGM guidelines and consensus

12:30

The essentials of glucose monitoring: FreeStyle Libre

12:50

Integrating FreeStyle Libre into clinical workflow: Reports and interpretation*Speakers: Hussain, Syed Sufyan (United Kingdom) & Mader, Julia (Austria)*

13:35

Question and answers and closing remarks*All Faculty*

PROGRAMME

TUESDAY 8 APRIL

12:30 - 13:30 Amber

P&G Health: Shape the future of nerve health - Empower the patient

12:30 **Welcome and introduction**
Chair: *Boulton, Andrew (United Kingdom)*

12:35 **Diabetic neuropathy: Can we do better?**
Speaker: *Malik, Rayaz (Qatar)*

12:55 **The new ACT tool – empowering the patient to act**
Speaker: *Gad, Hoda (Qatar)*

13:05 **Validation of ACT tool in Latin America: Ecuador Pilot**
Speaker: *Solis Sanchez, C. (Ecuador)*

13:15 **Solving the puzzle of diabetic peripheral neuropathy**
Panel discussion, international expert panel

12:30 - 13:30 Grand Hall 201

Abbott Nutrition: Implementing MNT in diabetes management: Time to move the needle

12:30 **Welcome and introduction**
Chair: *Dimaano Jr, Jose Rodolfo (Philippines)*

12:35 **MNT in diabetes management: A critical appraisal**
Panellists: *Chee, Winnie (Malaysia); Deerochanawong, Chaicharn (Thailand) & Mohan, Viswanathan (India)*

13:10 **Translating the latest evidence of MNT in diabetes management**
Speaker: *Tey, Siew Ling (Singapore)*

13:25 **Concluding remarks**
Chair: *Dimaano Jr, Jose Rodolfo (Philippines)*

12:30 - 13:30 Grand Hall 202

Sciarc: Optimising care in heart failure, chronic kidney disease and diabetes with non-steroidal MRAs

12:30 **Welcome and introduction**
Chair: *Ji, Linong (China) & Cheng, Alice (Canada)*

12:35 **Kidney disease in type 1 and type 2 diabetes: Bridging the gaps**
Speaker: *Groop, Per-Henrik (Finland)*

12:50 **New paths to improve outcomes in heart failure**
Speaker: *McMurray, John (United Kingdom)*

13:05 **Non-steroidal MRAs in cardiovascular, kidney, and diabetes care: practical considerations**
Speaker: *Van Gaal, Luc (Belgium)*

13:20 **Discussion and closure**
Chairs: *Ji, Linong (China) & Cheng, Alice (Canada)*

Organized by Sciarc, kindly supported by Bayer AG.

12:30 - 13:30 Nile 1

Lilly: New insights into treatment of type 2 diabetes

12:30 **Welcome and introduction**
Chair: *Lynch, Amber*

12:33 **Is progression of β -cell dysfunction in type 2 diabetes inevitable?**
Speaker: *Hussain, Sufyan*

12:53 **GIP and GLP-1 receptor agonist mechanism of action in type 2 diabetes**
Speaker: *Rachman, Jonathan*

13:13 **Panel question and answer**
All faculty

13:28 **Summary and close**
Chair: *Lynch, Amber*

12:30 - 13:30 Nile 2

AusMedGlobal: The beauty and opportunity of breath ketone to transform diabetes care

12:30

Welcome and introduction

Chair: *Yip, Christine (Hong Kong, China)*

12:35

Ketone measurements in diabetes management

Speaker: *Chi-Ho Lee, Paul (Hong Kong, China)*

12:50

The synergy of AI driven digital twin technology and breath ketone measurement for diabetes care

Speaker: *Dong, Joe (Hong Kong, China)*

13:05

Efficacy and safety of GLP1Ra combination therapy: a population-based cohort study

Speaker: *Tse, Gary (Hong Kong, China)*

13:20

Question and Answers

All Faculty

17:30 - 19:30 Nile 2

Lilly: Global Health session "How the private sector can help improve access to health care: A case of Lilly"

17:30

Access to healthcare landscape – supply- and demand-side barriers to access

17:40

Strategic collaborations to advance access to health care – LFAC/DR Cold Chain, A4D

18:00

Access expansion to insulins – collaboration with EVA Pharma

18:15

VLA as an access expansion tool

18:25

Panel discussion -

WHO PQ or Regional Offices, Life for A Child, Action for Diabetes, EVA Pharma, Egypt MOH

All Faculty

18:45

Question and Answers

All Faculty

12:30 - 13:30 Silk 1

Servier: Assessing and addressing needs in T2D for glycaemic control, cardiorenal protection and adherence: What are our options?

12:30 **Welcome and introduction**
Chair: *Khunti, Kamlesh (United Kingdom)*

12:35 **Glycaemic control and Cardiorenal benefits: Together or one over the other?**
Speakers: *Chan, Juliana (Hong Kong, China) & Mehta, Ashwani (India)*

12:50 **The paramount importance of glycaemic control: What are our options?**
Speaker: *Hassanein, Mohamed M (United Arab Emirates)*

13:05 **Simplifying adherence for people with type 2 diabetes: What are the unmet needs**
Speakers: *Dichpally, Narsimha Raju (India) & Iqtadar, Somia (Pakistan)*

13:20 **Discussion**
All Faculty

17:30 - 19:30 Silk 2

Abbott: From Namaste to Sawasdee: A night of continuous connection

17:30 **Opening Remarks and Introductions**
Chair: *Lee, Kenneth (Singapore)*

17:40 **From data to decisions: Leveraging CGM for clinical excellence**
Speaker: *Garg, Satish (USA)*

18:10 **From BGM to CGM: Enhancing diabetes care In India with cost-effective monitoring**
Speaker: *Mohan, Viswanathan (India)*

18:40 **Speed networking: Ignite continuous connections**
All Faculty

19:25 **Closing**
Chair: *Lee, Kenneth (Singapore)*

12:30 - 13:30 Meeting Room 216

WHO: Bridging gaps: Integrated strategies to address TB and Diabetes

12:30 **Introduction**

12:35 **Overview of burden and latest WHO guidance to address TB and Diabetes**

Speaker: *Baddeley, Annabel (Switzerland)*

12:50 **Impact and feasibility of integrated TB and Diabetes care - synthesis of the evidence and research gaps**

Speaker: *Nyirenda, John L.Z. (Germany)*

13:05 **Panel discussion: Scaling up collaborative action on TB and diabetes - challenges, opportunities, and what will it take?**

People with lived experience of TB and diabetes

13:25 **Round up**

PROGRAMME

WEDNESDAY 9 APRIL

12:30 - 13:30 Amber

Roche Diabetes Care: Holistic and connected diabetes management: Insights from the patient's perspective

12:30

Introduction

Chair: *Basit, Abdul (Pakistan) & Stroilă, Andrei (Romania)*

12:35

The transformative impact of emotional support and education of digital diabetes technology

Speaker: *Chan, Juliana (Hong Kong, China)*

12:50

Empowering patients through blood glucose monitoring: Fostering ownership and enhancing lifestyle behaviors

Speaker: *Kesavadev, Jothydev (India)*

13:05

Collaboration in action: Bridging healthcare support and patient-driven decisions in diabetes management

Speaker: *Laichuthai, Nitchakam (Thailand)*

13:20

Discussion and Closing

All Faculty

12:30 - 13:30 Diabetes Spotlight

P&G Health: Breaking barriers in peripheral neuropathy management- From silent suffering to superior treatment

12:30

Welcome and introduction

Chair: *Yan, Li (Singapore)*

12:35

One-stop-shop diagnosis of diabetic complications and diabetic peripheral neuropathy

Speaker: *De La Pena, Pepito (Philippines)*

12:50

Role of high-dose neurotropic B vitamins in the management of peripheral neuropathy

Speaker: *Taslim, Pinzon Rizaldy (Indonesia)*

13:05

Safe use of vitamin B6 in management of peripheral neuropathy

Speaker: *Kulkantrakorn, Kongkiat (Thailand)*

13:20

Questions and answers

All Faculty

17:30 - 18:30 Grand Hall 201

**WHO & IDF: 4th WHO Global Diabetes Compact anniversary:
Achieving five diabetes targets in five years:
Is integration to PHC/UHC the key?**

17:30 **Opening remarks**17:36 **WHO Global Diabetes Compact: Four years of progress**Speaker: *Fones, Guy (Chile)*17:46 **Panel discussion on integration of diabetes into PHC/UHC**18:21 **Quiz**18:28 **Closing message: Five years towards global diabetes targets**Chair: *Fones, Guy (Chile)*

12:30 - 13:30 Grand Hall 202

**Abbott: Revolutionising diabetes care with CGM:
Innovation for accessibility and ease**

12:30 **Welcome and introduction**Chair: *Santiprabhob, Jeerunda (Thailand)*12:35 **CGM as the standard of care**Speaker: *Garg, Satish (USA)*12:50 **CGM to elevate quality of life**Speaker: *Cheng, Alice (Canada)*13:05 **CGM access for all?**Speaker: *Mohan, Viswanathan (India)*13:20 **Questions and answers and closing**

All Faculty

12:30 - 13:30 Nile 1

Lilly: Seeing beyond the numbers in type 2 diabetes: Empowering patients for optimal weight and glycaemic management

12:30 **Welcome and Introduction: Challenges in weight and glycaemic management**

Chair: *Davies, Melanie (United Kingdom)*

Following patient journeys:

12:35 **Integrating weight and glycaemic management:**

Overcoming clinical inertia and barriers to effective treatment

12:50 **Utilising shared decision-making in treatment choices**

13:05 **Incorporating multidisciplinary team approaches**

Speakers: *Kadowaki, Takashi (Japan) & Kellerer, Monika (Germany)*

13:20 **Summary, questions and answers**

All Faculty

17:30 - 19:00 Nile 2

JAPI: Advance in diabetes management and metabolic health: Perspectives from India and SEA

17:30 **Welcome and introduction**

17:35 **Evolution of combination therapy: Evidence-based approach to diabetes management**

17:55 **Optimising patient outcomes: When and how to initiate**

18:15 **Beyond glycaemic control: Cardiovascular and renal benefits of modern treatment**

18:35 **Discussion: Practical challenges and solutions in diabetes management**

18:55 **Closing remarks**

12:30 - 13:30 Silk 1

Merck: Metformin and insulin resistance: Bridging science and clinical practice

- 12:30 **Welcome and introduction**
Chair: *Deerochanawong, Chaicharn (Thailand)*
- 12:35 **Metformin in early and impending diabetes**
Speaker: *Nicodemus, Nemencio Jr. (Philippines)*
- 12:50 **Metformin in PCOS**
Speaker: *Joham, Anju (Australia)*
- 13:05 **Metformin during pregnancy**
Speaker: *Boriboonthirunsarn, Dittakarn (Thailand)*
- 13:20 **Questions and answers**
All Faculty

12:30 - 13:30 Silk 2

Hetero: Early combinational therapy of DPP-4i Plus SGLT2i: Patient profile, approaches, strategies, guidelines and pitfalls

- 12:30 **Welcome and opening remarks**
Chair: *Vichayanrat, Apichati (Thailand)*
- 12:40 **Early combinational therapy of DPP-4i Plus SGLT2i**
Speaker: *Schwarz, Peter (Germany)*
- 13:10 **Questions and answers**
All faculty
- 13:25 **Closing remarks and summary**

The IDF 2025 Congress is mobile!



Download the congress app to:

- receive up-to-date programme information
- create your own schedule
- locate sessions and exhibitor booths with ease
- learn about speakers and exhibitors



Search for IDF 2025

Share your congress moments

   **#IDF2025**